Oryzon Genomics (Spain) Today
| ORY Stock | EUR 1.56 0.01 0.64% |
Performance0 of 100
| Odds Of DistressLess than 28
|
Oryzon Genomics is trading at 1.56 as of the 22nd of November 2024, a 0.64% down since the beginning of the trading day. The stock's open price was 1.57. Oryzon Genomics has about a 28 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Oryzon Genomics SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. The company has 55.56 M outstanding shares. More on Oryzon Genomics SA
Moving together with Oryzon Stock
Moving against Oryzon Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Oryzon Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Oryzon Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Oryzon Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman of the Board | Carlos Arjol |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Oryzon Genomics SA (ORY) is traded on Madrid Exchange in Spain and employs 43 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 140.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oryzon Genomics's market, we take the total number of its shares issued and multiply it by Oryzon Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Oryzon Genomics SA operates under Biotechnology sector and is part of Health Care industry. The entity has 55.56 M outstanding shares.
Oryzon Genomics SA has accumulated about 29.11 M in cash with (3.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Check Oryzon Genomics Probability Of Bankruptcy
Ownership AllocationOryzon Genomics owns a total of 55.56 Million outstanding shares. Oryzon Genomics holds 18.04 pct. of its outstanding shares held by insiders and 0.72 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Oryzon Ownership Details
Oryzon Genomics SA Risk Profiles
Although Oryzon Genomics' alpha and beta are two of the key measurements used to evaluate Oryzon Genomics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.04 | |||
| Standard Deviation | 1.5 | |||
| Variance | 2.26 | |||
| Risk Adjusted Performance | (0.09) |
Oryzon Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Oryzon Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Oryzon Genomics Corporate Management
Elected by the shareholders, the Oryzon Genomics' board of directors comprises two types of representatives: Oryzon Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oryzon. The board's role is to monitor Oryzon Genomics' management team and ensure that shareholders' interests are well served. Oryzon Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oryzon Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saikat Nandi | Global Officer | Profile | |
| Emili Cortada | Chief Officer | Profile | |
| Xavier Ribera | Head Compliance | Profile | |
| Michael Ropacki | Chief CNS | Profile | |
| Sonia Bezon | Chief Operations | Profile | |
| Jordi Pey | Chief Officer | Profile |
Other Information on Investing in Oryzon Stock
Oryzon Genomics financial ratios help investors to determine whether Oryzon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.